Adedayo Adedoyin - Concepedia

Author

Adedayo Adedoyin

Also Known As

A ADEDOYIN, A Adedoyin, A. Adedoyin, A. E. Adedoyin, Adedayo Adedoyin, Adedayo B. Adedoyin, Adedoyin, Adedayo B., Adeola Oluwaseun Adedoyin, Sreeraj Macha

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University University of Pittsburgh Merck & Co., Inc., Rahway, NJ, USA (United States)University of Pittsburgh Medical Center Princeton University

About

Adedayo Adedoyin is an author at Vanderbilt University specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	575
2	Biochemistry	4	4	173
3	Health Sciences	1	1	40
4	Natural Sciences	1	1	10
5	Social Sciences	1	1	26

Adedayo Adedoyin

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Validation of the five-drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug-metabolizing enzymes* Reginald F. Frye, Gary R. Matzke, Adedayo Adedoyin, Clinical Pharmacology & Therapeutics	1997	241
Obtaining Exposures of Metabolites in Preclinical Species through Plasma Pooling and Quantitative NMR: Addressing Metabolites in Safety Testing (MIST) Guidance without Using Radiolabeled Compounds and Chemically Synthesized Metabolite Standards Karthick Vishwanathan, Kathlene Babalola, Jack Wang, Chemical Research in Toxicology Metabolomic ProfilingDrug MetabolitesChemical SafetyDrug PurityBioanalysis	2008	98
Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6* Adedayo Adedoyin, Patricia A. Arns, William O. Richards, Clinical Pharmacology & Therapeutics	1998	97
Differences in plasma binding of drugs between Caucasians and Chinese subjects Hong-Hao Zhou, Adedayo Adedoyin, G. Wilkinson Clinical Pharmacology & Therapeutics Chinese SubjectsDrug DispositionPharmacotherapyDrug ClassPlasma Binding	1990	90
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies Adedayo Adedoyin, J F Bernardo, Christine E. Swenson, Antimicrobial Agents and Chemotherapy Nonlinear PharmacokineticsPharmaceutical ScienceAntifungal AgentPharmacological StudyPharmacokinetic Profile	1997	90
Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil Jacqueline B. McCrea, Sreeraj Macha, Adedayo Adedoyin, The Journal of Clinical Pharmacology	2019	82
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection Vicente Boix, Richard N. Fedorak, Kathleen M. Mullane, Open Forum Infectious Diseases	2017	71
Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial Peter Daley, Thomas Louie, J E Lutz, Journal of Antimicrobial Chemotherapy	2017	70
Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail Adedayo Adedoyin, Reginald F. Frye, Kelly Mauro, British Journal of Clinical Pharmacology	1998	66
A phase II trial of all- trans -retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis D L Trump, David C. Smith, Dwight D. Stiff, Cancer Chemotherapy and Pharmacology UrologyMedicineDetailed Pharmacokinetic AnalysisPharmacologyAll- Trans	1997	66

Page 1